Expressive Writing for COVID-19 Resilience for Parents

Sponsor
Duke University (Other)
Overall Status
Completed
CT.gov ID
NCT04589117
Collaborator
(none)
11
1
1
2.2
5

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the impact of a 4-week, virtually-delivered expressive writing intervention on resilience in a cohort of parents and caregivers currently navigating the COVID-19 pandemic during spring & summer of 2020.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Expressive writing
N/A

Detailed Description

In 2016, the research team piloted a 6-week intervention on expressive writing for resilience in a population of trauma survivors. Participants self-identified as having had a recent trauma or significant life upheaval, such as a divorce, major illness, job loss, or the death of a loved one. At 6 weeks, the investigators found that participants experienced significantly improved levels of resilience and lower levels of stress, rumination, and depression. These results added to a growing body of research indicating the potential for expressive writing to be a powerful healing modality for both psychological and physical well-being.

The current COVID-19 pandemic presents the potential for trauma or significant life upheaval for nearly all members of the community and the world at large. Parents of children who are at home face unique challenges during this time. Social distancing guidelines, shelter in place protocols, school and business closures, travel restrictions, high levels of job loss, loss of childcare, and the looming threat of illness have disrupted daily routines, family life, and significantly altered life plans for many. Parents and caregivers who have unexpectedly lost childcare, are having to adjust to home schooling arrangements, and/or are having to end to heightened emotional needs in their children may experience this time as particularly difficult.

Resilience is the capacity for individuals to adapt and recover in the face of trauma, adversity, or significant sources of stress. The current collective reality magnifies the need for accessible, low-cost, effective interventions to help people cultivate resilience and other dimensions of psychological well-being.

In this study, the investigators seek to further the work the research team began in 2016 with a 4-week, virtually-delivered expressive writing intervention designed to support parents in cultivating personal resilience and emotional wellness during the COVID-19 pandemic.

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Expressive Writing for COVID-19 Resilience for Parents
Actual Study Start Date :
May 27, 2020
Actual Primary Completion Date :
Aug 2, 2020
Actual Study Completion Date :
Aug 2, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Expressive writing

The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email. The progression of writing exercises flows as follows: Week 1: Writing to expressive difficult emotions Week 2: Writing to cultivate compassion & forgiveness Week 3: Writing to nurture positive emotions Week 4: Writing to invite insight, perspective, & growth

Behavioral: Expressive writing
The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email. The progression of writing exercises flows as follows: Week 1: Writing to expressive difficult emotions Week 2: Writing to cultivate compassion & forgiveness Week 3: Writing to nurture positive emotions Week 4: Writing to invite insight, perspective, & growth

Outcome Measures

Primary Outcome Measures

  1. Resilience [3 months]

    Connor-Davidson Resilience Scale (CD-RISC)

Secondary Outcome Measures

  1. Perceived stress [3 months]

    Perceived Stress Scale-10 (PSS-10)

  2. Depression symptoms [3 months]

    Center for Epidemiologic Studies Depression Scale Revised (CESDR)

  3. Parental stress [3 months]

    Internal, non-validated questionnaire re. experience of parental stress

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

In order to have up to 40 evaluable subjects, we plan to consent up to 45 individuals. Potential subjects will be considered eligible if they are parents or primary caregivers of children aged 0-18 who have been home with them during the COVID-19 experience. Other eligibility criteria include:

  • Able to speak, read, write, and understand English

  • Cognitively able to provide consent

  • Ability to participate in a 4-week intervention delivered via Zoom and email

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke Integrative Medicine Durham North Carolina United States 27705

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Oliver Glass, PhD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT04589117
Other Study ID Numbers:
  • Pro00105586
First Posted:
Oct 19, 2020
Last Update Posted:
Nov 24, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2021